THORNTON JOSEPH CLAY sold $110K of CLOV

THORNTON JOSEPH CLAY (Chief Financial Officer) sold 22,099 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.97 ($0.11M total) on 2026-11-16.

Original reporting
SEC EDGAR · THORNTON JOSEPH CLAY
Published Nov 17, 2026, 10:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 10:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Bearish
medium confidence
Mentioned
$CLOV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVBearishLow
01

Why it matters

The only new information is the CFO’s open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may briefly reassess sentiment around CLOV due to insider selling, but the filing does not provide a fundamental driver.

03

What to watch

No 10b5-1 plan is cited, but the filing alone does not reveal the insider’s cost basis, tax considerations, or whether other planned sales occurred.

Relevance 4/10Novelty 5/10Timing: filed 2026-11-17, transaction dated 2026-11-16

Background

The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp. (CLOV).

Company-level read

Ticker impact

$CLOVBearishMedium confidence
Context

Clover Health CFO Thornton Joseph Clay sold 22,099 shares at $4.97 on 2026-11-16, per a new SEC Form 4 filing.

Expected impact

Likely limited near-term pressure as traders weigh the sale against broader fundamentals.

Evidence & confidence

The disclosure is a routine Form 4 insider transaction with no stated 10b5-1 plan and no accompanying operational or guidance change.

Market effects

Minimal, as this is company-specific insider selling with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity management and does not necessarily reflect bearish expectations, especially without evidence of a broader change in fundamentals.

Key entities

  • CLOVER HEALTH INVESTMENTS, CORP. /DE

    US-listed company whose CFO filed the insider sale on Form 4.

  • THORNTON JOSEPH CLAY

    Clover Health CFO who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.